Therapeutic drug monitoring of oral targeted antineoplastic drugs.

Anna Mueller-SchoellStefanie L GroenlandOliver Scherf-ClavelMadelé van DykWilhelm HuisingaRobin MicheletUlrich JaehdeNeeltje SteeghsAlwin D R HuitemaCharlotte Kloft

Published in: European journal of clinical pharmacology (2020)

Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window.

Keyphrases

early onset
cancer therapy
drug induced